Page last updated: 2024-09-04

atrasentan and Local Neoplasm Recurrence

atrasentan has been researched along with Local Neoplasm Recurrence in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Groenewegen, G; Kronemeijer, RH; Los, M; van der Mijn, KJ; Voest, EE; Witteveen, PO	1
Antonia, S; Bepler, G; Boulware, D; Burton, M; Chiappori, AA; Haura, E; Kapoor, R; Lush, R; Neuger, AM; Padilla, B; Rodriguez, FA; Simon, G; Sullivan, DM; Williams, C	1
Carson, KA; Desideri, S; Fisher, JD; Grossman, SA; Lesser, G; Mikkelsen, T; Olson, J; Phuphanich, S	1

Trials

2 trial(s) available for atrasentan and Local Neoplasm Recurrence

Article	Year
Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer. Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:11 Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Pyrrolidines; Survival Analysis; Treatment Outcome; Vomiting	2010
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Mar-01, Volume: 14, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endothelin A Receptor Antagonists; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Pyrrolidines; Survival Rate	2008

Article

Year

Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.

Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:11

Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Pyrrolidines; Survival Analysis; Treatment Outcome; Vomiting

2010

Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Mar-01, Volume: 14, Issue:5

Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endothelin A Receptor Antagonists; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Pyrrolidines; Survival Rate

2008

Other Studies

1 other study(ies) available for atrasentan and Local Neoplasm Recurrence

Article	Year
Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro-oncology, 2008, Volume: 10, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Atrasentan; Brain Neoplasms; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pyrrolidines	2008